Browse News
Filter News
Found 315 articles
-
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
3/21/2024
MediWound Ltd., the global leader in next-generation enzymatic therapeutics for tissue repair, announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
-
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
3/14/2024
MediWound Ltd. today announced that the Company will release its financial results for the fourth quarter and full year ended December 31, 2023 on Thursday, March 21, 2024.
-
Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance
2/29/2024
Vericel Corporation, a leader in advanced therapies for the sports medicine and severe burn care markets, reported financial results and business highlights for the fourth quarter and year ended December 31, 2023, and provided full-year 2024 financial guidance.
-
Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024
2/27/2024
Vericel Corporation today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference at 11:10 a.m. ET on Tuesday, March 5, 2024.
-
Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024
2/15/2024
Vericel Corporation, a leader in advanced therapies for the sports medicine and severe burn care markets, announced that it will report its fourth-quarter and full-year 2023 financial results on Thursday, February 29, 2024.
-
MediWound to Participate in Two Upcoming Investor Conferences
2/5/2024
MediWound Ltd. today announced its participation in the upcoming Oppenheimer 34th Annual Life Sciences Conference, taking place virtually on February 13-14, 2024, as well as the upcoming TD Cowen 44th Annual Health Care Conference, taking place in Boston on March 4-6, 2024.
-
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024
2/5/2024
Vericel Corporation today announced that Nick Colangelo, President and CEO will present at the Canaccord Genuity Musculoskeletal Conference.
-
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
1/9/2024
MediWound Ltd. today announced that the U.S. Food and Drug Administration (FDA) has completed their filing review and accepted a supplement to the NexoBrid® biologics license application (sBLA) for the removal of eschar in pediatric patients with deep partial- and/or full-thickness thermal burns.
-
Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results
1/9/2024
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced preliminary, unaudited financial results for the fourth quarter and year ended December 31, 2023.
-
Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024
1/3/2024
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the 42nd Annual J.P. Morgan Healthcare Conference.
-
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
12/28/2023
MediWound Ltd. announced that the U.S. Department of Defense, through the Medical Technology Enterprise Consortium, has awarded MediWound an additional $6.7 million in non-dilutive funding to develop NexoBrid® as a non-surgical solution for field-care burn treatment for the U.S. Army.
-
MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
12/21/2023
MediWound Ltd. announced the publication of a peer-reviewed paper, titled “An Open-label, Proof of Concept Study, Assessing the Effects of Bromelain-Based Enzymatic Debridement on Biofilm and Microbial Loads in Patients with Venous Leg and Diabetic Foot Ulcers” in the December 2023 issue of WOUNDS Journal.
-
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
11/21/2023
MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, announced the appointment of Shmulik Hess, Ph.D. to the positions of Chief Operating Officer and Chief Commercial Officer effective as of December 1, 2023.
-
MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update
11/21/2023
MediWound Ltd., the global leader in next-generation enzymatic therapeutics for tissue repair, announced financial results for the third quarter ended September 30, 2023, and provided a corporate update.
-
Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
11/8/2023
Vericel Corporation today reported financial results and business highlights for the third quarter ended September 30, 2023.
-
MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in EuropeNexoBrid complements PMI’s portfolio, allowing it to provide a comprehensive solution for burn patients
11/8/2023
MediWound Ltd. (Nasdaq: MDWD) and PolyMedics Innovations (PMI), an innovative biomaterials company specializing in effective wounds treatment, today announced an agreement for the promotion of NexoBrid® in Germany, Austria, Belgium, the Netherlands and Luxemburg.
-
Vericel to Present at the Stephens Annual Investment Conference
11/7/2023
Vericel Corporation today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will present at the Stephens Annual Investment Conference.
-
Vericel to Report Third-Quarter 2023 Financial Results on November 8, 2023
10/25/2023
Vericel Corporation today announced that it will report its third-quarter 2023 financial results on Wednesday, November 8, 2023.
-
MediWound Announces Collaboration with 3M on EscharEx® Phase III StudyMediWound to join forces with 3M Health Care, world’s largest wound care company in pivotal study for patients with venous leg ulcers
10/11/2023
MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, announced collaboration with 3M Health Care.
-
MediWound Deploys NexoBrid® for Emergency Supply
10/9/2023
MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, addresses emergency demand for NexoBrid to treat the mass of burn casualties, inflicted by the war in Israel.